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Abstract
Background: Respiratory muscle contractile performance is impaired by diabetes, mechanisms of which included altered
carbohydrate and lipid metabolism, oxidative stress and changes in membrane electrophysiology. The present study
examined to what extent these cellular perturbations involve changes in gene expression.
Methodology/Principal Findings: Diaphragm muscle from streptozotocin-diabetic rats was analyzed with Affymetrix gene
expression arrays. Diaphragm from diabetic rats had 105 genes with at least 62-fold significantly changed expression (55
increased, 50 decreased), and these were assigned to gene ontology groups based on over-representation analysis using
DAVID software. There was increased expression of genes involved in palmitoyl-CoA hydrolase activity (a component of
lipid metabolism) (P=0.037, n=2 genes, fold change 4.2 to 27.5) and reduced expression of genes related to carbohydrate
metabolism (P=0.000061, n=8 genes, fold change 22.0 to 28.5). Other gene ontology groups among upregulated genes
were protein ubiquitination (P=0.0053, n=4, fold change 2.2 to 3.4), oxidoreductase activity (P=0.024, n=8, fold change
2.1 to 6.0), and morphogenesis (P=0.012, n=10, fold change 2.1 to 4.3). Other downregulated gene groups were
extracellular region (including extracellular matrix and collagen) (P=0.00032, n=13, fold change 22.2 to 23.7) and
organogenesis (P=0.032, n=7, fold change 22.1 to 23.7). Real-time PCR confirmed the directionality of changes in gene
expression for 30 of 31 genes tested.
Conclusions/Significance: These data indicate that in diaphragm muscle type 1 diabetes increases expression of genes
involved in lipid energetics, oxidative stress and protein ubiquitination, decreases expression of genes involved in
carbohydrate metabolism, and has little effect on expression of ion channel genes. Reciprocal changes in expression of
genes involved in carbohydrate and lipid metabolism may change the availability of energetic substrates and thereby
directly modulate fatigue resistance, an important issue for a muscle like the diaphragm which needs to contract without
rest for the entire lifetime of the organism.
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Introduction
Diabetes mellitus impairs respiratory muscle function in humans
with type 1 diabetes, as evidenced by findings of reduced vital
capacity, peak esophageal and transdiaphragmatic pressures,
maximal voluntary ventilation, and ability of the respiratory
muscles to maintain a target force over time [1–3]. Studies in
animal models of type 1 diabetes have confirmed reduced strength
and endurance in respiratory and other skeletal muscles [4–10].
Diabetes-induced skeletal muscle dysfunction likely contributes to
the reduced exercise capacity of humans with both type 1 [11] and
type 2 [12,13] diabetes, and may account for a portion of the
increased sensation of dyspnea in humans with diabetes when
ventilation or respiratory efforts are increased [3,14].
Several cellular mechanisms underlying these adverse contrac-
tile changes have been identified from biochemical and electro-
physiological studies of diaphragm muscle in animal models of
diabetes. A well-established alteration is a shift in cellular
energetics away from carbohydrate metabolism [15–22] and
towards lipid metabolism [22–25]. There is also evidence for
increased oxidative stress [6]. In addition there are perturbations
in muscle electrophysiological properties involving resting mem-
brane potential and action potential [7,26,27]. The extent to
which these events involve changes in gene expression, and
whether there are also changes in gene expression involving
additional processes implicated in diabetes-induced dysfunction in
other tissues (eg. protein ubiquitination), has not been elucidated
previously for the respiratory muscles.
Alterations in gene expression with diabetes are prominent in
many tissues, including pancreas [28], kidney [29–31], liver [32],
spleen [33], adipose tissue [32], eye [34], corpus cavernosum [35],
heart [36–38] and limb skeletal muscle [32,39–41], albeit with
important differences among tissue types. Normal diaphragm and
limb skeletal muscles differ considerably in their patterns of gene
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from limb muscle with respect to the degree and nature of
alterations in gene expression in response to other diseases [42–
44]. Thus previous data on limb muscle gene expression responses
to diabetes [32,39–41] are unlikely to apply directly to the
diaphragm, in particular with respect to which specific genes
undergo altered expression, the magnitude of these expression
changes, and whether there are changes in gene expression related
to cellular energetics. The purpose of the present study was to
examine global alterations in gene expression of the diaphragm
muscle in response to type 1 diabetes mellitus. We hypothesized
that there would in particular be alterations in gene expression
involving lipid and carbohydrate metabolism, oxidative stress and
membranous ion channels.
Methods
All studies were approved by the institutional animal care and
use committee and conformed with NIH guidelines for animal
care. Studies were performed on six male Wistar rats obtained
from Charles River Laboratories (Wilmington, MA); cardiac data
from these animals have been reported previously [38]. At an age
of eight weeks, half of the animals were injected intraperitoneally
with streptozotocin 60 mg/kg dissolved in sodium citrate buffer,
and the other half with buffer alone. Four weeks later they were
well-anesthetized with a mixture of intraperitoneal ketamine,
xylazine and acepromazine following an all-night fast. Blood
obtained from the tail was analyzed for glucose using a glucometer
(Lifescan, Milpitas, CA). The entire costal diaphragm muscle was
removed surgically, placed in RNAlater, and stored at 280uC;
only the left hemidiaphragm was used as this provided sufficient
tissue for RNA isolation. At the time of muscle removal, fasting
blood glucose values were 7064 mg/dl (range 62–76) for the
normal animals, and 279615 mg/dl (range 254–306) for the
diabetic animals (P,0.001 by unpaired t test). The normal animals
all gained weight during the four weeks following buffer injection
(average 9466 grams) whereas the diabetic animals lost 4–5% of
their weight during the four weeks following streptozotocin
injection (average 1161 grams). Animals were not treated with
insulin or oral hypoglycemics because the purpose of the study was
to determine the effects of diabetes on diaphragm gene expression
rather than the extent to which treatment of diabetes would
attenuate the changes.
Gene expression array studies were performed in a manner
similar to that described previously [38,45,46]. Total RNA was
extracted using Trizol (GibcoBRL, Rockville, MD), and the RNA
pellets were resuspended at 1 mg RNA/ml DEPC-treated water.
This was followed by a cleanup protocol with a Qiagen (Valencia,
CA) RNeasy Total RNA mini kit. Total RNA was prepared for
use on Affymetrix (Santa Clara, CA) microarrays, according to the
directions from the manufacturer. Briefly, 8 mg of RNA was used
in a reverse transcription reaction (SuperScript II; Life Technol-
ogies, Rockville, MD) to generate first strand cDNA. After second
strand synthesis, double strand cDNA was used in an in vitro
transcription reaction to generate biotinylated cRNA. This was
purified and fragmented, following which 15 mg of biotin-labeled
cRNA was used in a 300 ml hybridization cocktail which included
spiked transcript controls. 200 ml of cocktail was loaded onto
Affymetrix RAE 230A microarrays (Santa Clara, CA) and
hybridized for 16 hr at 45uC with agitation. Standard post-
hybridization washes and double-stain protocols used an Affyme-
trix GeneChip Fluidics Station 400. Arrays were scanned using a
Hewlett Packard Gene Array scanner, and analyzed with
Affymetrix MAS 5.0 software. The data have been deposited in
NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.
nih.gov/geo/) and assigned Series accession number GSE4653.
Gene expression array studies are critically dependent on high
quality RNA both before and after the IVT amplification. Quality
control values from the present study are as follows: 260/280 nm
optical density prior to IVT of 1.97 to 2.18, RIN number from
Agilent Bioanalyzer of 8.9 to 9.2, yield of RNA from IVT reaction
of 71 to 129 micrograms, percent present calls on each array of 56
to 64 percent, betaActin 39/M ratio of 1.4 to 2.3, betaActin 39/59
ratio of 1 to 1.4, GADPH 39/M ratio of 1 to 1.4, and GAPDH 39/
59 ratio of 1.1 to 1.8.
Statistical analysis was done with Bayesian analysis of variance
for microarrays (BAM), using BAMarray software (http://www.
bamarray.com) [47]. BAM balances the number of false detections
against false non-detections by means of a special type of
inferential regularization (i.e. borrowing strength across the data).
Genes identified by BAM as having significantly changed
expression were then further selected based on consistent and
appropriate present and absent calls in all three samples of each
group per Affymetrix software (marginal calls were accepted only
if that gene was called present for all other samples in that group).
Subsequently signals were averaged for muscle from the non-
diabetic and from diabetic animals, and fold changes were
calculated based on average values from each group. Analysis
focused on genes whose expression changed at least 62 fold in
diabetic compared with control muscle, unless indicated otherwise.
To assign biological meaning to the group of genes with changed
expression, the subset of genes which met the above criteria was
analyzed with the Gene Ontology (GO) classification system, using
DAVID software (http://apps1.niaid.nih.gov/david/) [48]. Over-
representation of genes with altered expression within specific GO
categories was determined using the one-tailed Fisher exact
probability modified by the addition of a jackknifing procedure,
which penalizes the significance of categories with very few (eg.
one or two) genes and favors more robust categories with larger
numbers of genes [49].
Real-time PCR (RT-PCR) was used to confirm changes in gene
expression as described previously [38,45,46]. Testing was done
using the same tissue that had been used for gene expression
arrays, and was performed for 31 genes. Genes which underwent
PCR testing were chosen from specific, statistically over-repre-
sented, GO groups: palmitoyl-CoA hydrolase activity, protein
ubiquitination, oxidoreductase activity, carbohydrate and alcohol
metabolism, extracellular matrix and collagen. One gene not from
one of these groups was also chosen for PCR testing due to an
important role in muscle contraction (parvalbumin). An Applied
Biosystems ABI 7900HT unit with automation attachment (Foster
City, CA) was used for real-time PCR. This unit is capable of
collecting spectral data at multiple points during a PCR run. To
execute the first step and make archive cDNA, 3 mg of total RNA
were reverse transcribed in a 100 ml reaction using Applied
Biosystems enzymes and reagents in accordance with the
manufacturer’s protocols. RNA samples were accurately quanti-
tated using a Nanodrop Technologies ND-1000 spectrophotom-
eter (Wilmington, DE). Equal amounts of total RNA were reverse
transcribed and then used in PCR amplifications. b-Actin had very
little variation in expression across the sample set and therefore
was chosen as the endogenous control. Since many of the target
genes of interest were signaling molecules and likely to be
expressed at low levels, we opted for a low dilution factor so as
to create an environment more conducive to obtaining reliable
results. The cDNA reaction from above was diluted by a factor of
10. For the PCR step, 9 ml of this diluted cDNA were used for
each of three replicate 15 ml-reactions carried out in a 384 well
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assay catalog numbers are listed in Appendix S1. Standard PCR
conditions were used for the Applied Biosystems assays: 50uC for
2 min, followed by 95uC for 10 min, followed by 40 cycles of 95uC
for 15 sec alternating with 60uC for 1 min each. rtPCR analysis
was similar to our previous study [38,45,46]. Values for RNA
abundance were normalized for each gene with respect to the
endogenous control in that sample (b-Actin), mean values for fold
changes were calculated for each gene, and statistical testing was
performed with the unpaired t-test.
Results
There were 55 genes with significantly increased expression and
50 genes with significantly reduced expression in diabetic
compared with normal diaphragm, using the cut-off of at least a
62-fold changed expression in addition to consistent present calls
by Affymetrix software and statistical signficance by BAM. A
complete list of these genes, including mean fold change values for
each gene, is provided in Appendix S2. Using lower fold-change
thresholds also resulted in findings of roughly equal numbers of
genes with increased and decreased expression, eg. 144 increases
versus 136 decreases using a 61.5-fold change threshold.
Classification of genes by Gene Ontology (GO) groups and
statistical testing of over-representation among GO groups was
done separately for genes with increased and reduced expression.
Genes with at Least 2-Fold Increased Expression in
Diabetic Diaphragm
Among the 55 genes with at least 2-fold increased expression,
assignment to GO groups was possible for 43 using the biological
functionclassification,41usingthemolecularfunctionclassification,
and 31 using the cellular constituent classification. The GO terms
with over-representation among these genes are indicated in
Table 1. The largest group with respect to both degree of
significance and number of genes (n=30) was the molecular
function term catalytic activity. The other group with a large
number of genes (n=23) was the cellular constituent term
intracellular. Four more specific groups each with smaller numbers
of genes were found as well. The first group, palmitoyl-CoA
hydrolase activity (a molecular function term), contained two genes.
The second group was comprised of four genes related to
ubiquitination and ubiquitin-ligase actvity, which appeared under
the biological process, molecular function and cellular constituent
classifications. The third was a group of eight genes relating to the
molecular function term oxidoreductase activity. The fourth group
was comprised of a number of different GO biological process terms
relating to development, morphogenesis and organogenesis, with a
total of ten genes. The genes with increased expression which
comprised someof the more specific GO terms are listed in Table 2.
Table 1. Gene ontology groups with significant over-
representation among genes with $2-fold increased
expression in diabetic.
GO Classification Specific GO Term
Number of
Genes P Value
Biological Process Protein Ubiquitination 4 0.0053
Morphogenesis 10 0.012
Bone Mineralization 3 0.012
Bone Remodelling 3 0.035
Organogenesis 8 0.047
Skeletal Development 3 0.048
Organ Development 8 0.048
Molecular Function Catalytic Activity 30 0.000034
Ligase Activity, Forming
Carbon-Nitrogen Bonds
5 0.001
Ubiquitin-Protein Ligase Actvitity 4 0.0038
Ligase Actvitity 5 0.0054
Oxidoreductase Activity 8 0.024
Palmitoyl-CoA Hydrolase Activity 2 0.037
Cellular Constituent Ubiquitin Ligase Complex 4 0.0033
Intracellular 23 0.017
P values reflect statistical significance of each GO term being over-represented
among genes with increased expression.
doi:10.1371/journal.pone.0007832.t001
Table 2. Genes with $2-fold increased expression in diabetic
diaphragm assigned to over-represented gene ontology
groups.
Gene Name
Gene
Symbol GeneID
Fold
Change
Palmitoyl-CoA Hydrolase Activity
cytosolic acyl-CoA thioesterase 1 Cte1 50559 27.5
mitochondrial acyl-CoA thioesterase 1 Mte1 192272 4.2
Protein Ubiquitination
tripartite motif-containing 63 Trim63 140939 3.4
F-box only protein 32 Fbxo32 171043 3.1
ring finger protein 39 Rnf39 171387 2.6
casitas B-lineage lymphoma b Cblb 171136 2.2
Oxidoreductase Activity
cytochrome P450, family 2, subfamily e,
polypeptide 1
Cyp2e1 25086 6.0
flavin containing monooxygenase 3 Fmo3 84493 2.9
crystallin, lamda 1 Cryl1 290277 2.4
lysyl oxidase Lox 24914 2.3
ceruloplasmin Cp 24268 2.2
2,4-dienoyl CoA reductase 1, mitochondrial Decr1 117543 2.2
aldehyde oxidase 1 Aox1 54349 2.1
P450 (cytochrome) oxidoreductase Por 29441 2.1
Morphogenesis, Organogenesis, and Organ
Development
endothelial cell-specific molecule 1 Esm1 64536 4.3
pregnancy-induced growth inhibitor Okl38 171493 4.0
musculoskeletal, embryonic nuclear protein 1 Mustn1 290553 3.2
osteomodulin Omd 83717 3.2
secreted phosphoprotein 1 Spp1 25353 2.9
serine (or cysteine) proteinase inhibitor,
clade E, member 1
Serpine1 24617 2.8
ring finger protein 39 Rnf39 171387 2.6
v-maf musculoaponeurotic fibrosarcoma
oncogene family, protein K (avian)
Mafk 246760 2.5
glycoprotein (transmembrane) nmb Gpnmb 113955 2.5
dual-specificity tyrosine-(Y)-phosphorylation
regulated kinase 1A
Dyrk1a 25255 2.1
doi:10.1371/journal.pone.0007832.t002
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Diabetic Diaphragm
Among the 50 genes with at least 2-fold reduced expression,
assignment to GO groups was possible for 33 using the biological
function classification, 41 using the molecular function classifica-
tion, and 29 using the cellular constituent classification. The GO
terms with over-representation among these genes are indicated in
Table 3. There were a number of specific GO terms that revolved
around the biological process theme of carbohydrate metabolism;
this included a total of eight genes, with considerable overlap
among these specific GO terms in constituent genes. A second
prominent group was the cellular constituent term extracellular
region containing 13 genes, which included more specific GO
terms such as extracellular matrix and collagen. The third group
was related to various molecular function terms dealing with
binding (12 genes). Finally there were seven genes related to GO
biological process themes organogenesis and organ development.
The genes with reduced expression which comprise three of the
more specific GO terms or groups of related GO terms are listed
in Table 4.
Genes with Lesser Degrees of Altered Expression
To determine whether other GO groups with over-represen-
tation maybepresentina largergroup ofgeneswithmoremodest
changes in expression, the GO group assignment was reanalyzed
using the 280 genes with at least 61.5-fold changed expression.
Most of the themes identified above in the smaller group of genes
with 62-fold changed expression were confirmed, and further-
more had larger numbers of constituent genes. Among genes with
increased expression, the ubiquitin group increased in size to 5
genes (from 4), the oxidoreductase group to 14 genes (from 8),and
the morphogenesis group to 19 genes (from 10). Among genes
with reduced expression, the carbohydrate metabolism group
grew to 13 genes (from 8), the extracellular matrix group grew to
11 genes (from 6), and the organogenesis group grew to 15 genes
(from 7).
Table 3. Gene ontology groups with significant over-
representation among genes with $2-fold reduced
expression in diabetic.
GO Classification Specific GO Term
Number of
Genes P Value
Biological Process Carbohydrate Metabolism 8 0.000061
Alcohol Metabolism 6 0.0077
Glucose Metabolism 5 0.0036
Alcohol Catabolism 4 0.0038
Cellular Carbohydrate Catabolism 4 0.0042
Cellular Carbohydrate Metabolism 5 0.005
Hexose Metabolism 5 0.0059
Monosaccharide Metabolism 5 0.0059
Glucose Catabolism 4 0.011
Hexose Catabolism 4 0.011
Monosaccharide Catabolism 4 0.011
Glycolysis 4 0.02
Organogenesis 7 0.032
Organ Development 7 0.033
Generation of Precursor
Metabolites and Energy
6 0.048
Molecular Function Extracellular Matrix Structural
Constituent
5 0.00001
Calcium Ion Binding 10 0.00003
Ion Binding 12 0.0013
Metal Ion Binding 12 0.0013
Cation Binding 10 0.0072
Cellular Constituent Collagen 4 0.00014
Extracellular Region 13 0.00032
Fibrillar Collagen 3 0.00033
Extracellular Matrix (Sensu
Metazoa)
6 0.0026
Extracellular Matrix 6 0.0027
Extracellular Space 8 0.011
Collagen Type V 2 0.018
Organelle Lumen 2 0.046
P values reflect statistical significance of each GO term being over-represented.
doi:10.1371/journal.pone.0007832.t003
Table 4. Genes with $2-fold reduced expression in diabetic
diaphragm assigned to over-represented gene ontology
groups.
Gene Name
Gene
Symbol GeneID
Fold
Change
Carbohydrate and Alcohol Metabolism
neuraminidase 2 Neu2 29204 28.5
phosphofructokinase, liver, B-type Pfkl 25741 23.7
solute carrier family 37 (glycerol-6-
phosphate transporter), member 4
Slc37a4 29573 22.5
glycerol-3-phosphate dehydrogenase 2 Gpd2 25062 22.3
amylase 1, salivary Amy1 24203 22.3
phosphoglycerate mutase 2 Pgam2 24959 22.1
lactate dehydrogenase A Ldha 24533 22.0
phosphoglucomutase 1 Pgm1 24645 22.0
dihydrolipoamide S-acetyltransferase (E2
component of pyruvate dehydrogenase
complex)
Dlat 81654 22.0
Extracellular Matrix and Collagen
collagen, type III, alpha 1 Col3a1 84032 23.7
collagen, type 1, alpha 1 Col1a1 29393 23.5
procollagen, type I, alpha 2 Col1a2 84352 23.2
fibrillin 1 Fbn1 83727 22.8
secreted acidic cysteine rich glycoprotein Sparc 24791 22.7
collagen, type V, alpha 1 Col5a1 85490 22.4
collagen, type V, alpha 3 Col5a3 60379 22.2
Organogenesis and Organ Development
collagen, type III, alpha 1 Col3a1 84032 23.7
Parvalbumin Pvalb 25269 23.1
acyl-CoA synthetase long-chain family
member 6
Acsl6 117243 22.7
ret proto-oncogene Ret 24716 22.5
chemokine (C-X-C motif) ligand 12 Cxcl12 24772 22.4
reticulon 4 Rtn4 83765 22.4
dimethylarginine dimethylaminohydrolase 1 Ddah1 64157 22.1
doi:10.1371/journal.pone.0007832.t004
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To confirm changes in gene expression, high throughput RT-
PCR was performed on a subset of 31 genes with at least 62-fold
changed expression (Table 5). Genes were chosen predominantly
from the following specific GO groups with over-representation
among genes with increased and decreased expression: palmitoyl-
CoA hydrolase activity, protein ubiquitination, oxidoreductase
activity, carbohydrate/alchohol metabolism, and collagen/extra-
cellular matrix. Among the 31 genes listed in Tables 2 and 4, the
direction of changes determined by PCR were in the same
direction as that determined by expression arrays in 30 cases
(97%). There was a good and statistically significant correlation
between the magnitude of altered expression measured by gene
expression array and that measured by RT-PCR for these genes
(Figure 1). In most instances, the changes measured by PCR were
statistically significant (Table 5).
Discussion
The present study found that changes in diaphragm gene
expression in a model of type 1 diabetes are divided almost equally
between increases and decreases. There was a small shift towards
genes involved in lipid metabolism, and a large shift away from
genes involved in carbohydrate metabolism, supporting our
hypothesis of diabetes altering the pattern of gene expression
related to energy metabolism. There was also increased expression
of genes related to oxidative stress (oxidoreductase activity), a
processes implicated previously in diabetes-induced diaphragm
dysfunction, as well as protein ubiquitination. On the other hand
expression of genes involved in collagen and extracellular matrix
formation was reduced, which in previous studies on limb muscle
has been attributed to muscle atrophy. Finally there was both
increased and decreased expression of genes related to morpho-
genesis, suggesting that there may be tissue remodelling occuring
in conjunction with muscle atrophy. The following discussion will
focus on type 1 diabetes.
Palmitoyl-CoA Hydrolase Activity
The two genes with increased expression that belonged to the
GO group palmitoyl-CoA hydrolase activity are involved in the
reaction palmitoyl-CoA+H2O=CoA+palmitate, an important
step in lipid metabolism (specifically long chain fatty acid
metabolism). Cte1 and Mte1 are the cytosolic and mitochondrial
forms respectively. Type 1 diabetes causes a 26-fold increased Cte1
expression in rat heart [38,50] as well as upregulated expression of
Mte1 in rodent limb skeletal and cardiac muscle [38,51]. Durgan et
al. [50] found that fatty acids upregulate cardiac Cte1 expression,
and that this involved regulatory roles for peroxisome proliferator-
activated receptor-a but not insulin. In the present study there was
another gene with 6-fold increased expression related to fatty acid
metabolism (albeit not assigned to an over-represented GO group),
namely Hmgcs2. The mitochondrial enzyme catalyzes a step in
Table 5. Changes in gene expression measured by real-time
PCR.
Gene Symbol
Fold Change by
Microarray
Fold Change
by PCR
P Value by
PCR
Cyp2e1 6.0 15.9 0.002
Trim63 3.4 10.7 0.004
Cte1 27.5 7.4 0.032
Rnf39 2.6 6.4 0.009
Fbxo32 3.1 4.5 0.002
Lox 2.3 4.2 0.001
Decr1 2.2 4.1 0.007
Fmo3 2.9 4.1 0.006
Aox1 2.1 3.7 0.006
Cblb 2.2 3.5 0.006
Mte1 4.2 3.4 0.003
Cp 2.2 2.7 0.117
Por 2.1 2.2 0.017
Cryl1 2.4 1.9 0.172
Pfkl 23.7 1.2 0.396
Gpd2 22.3 21.1 0.488
Dlat 22.0 21.2 0.128
Amy1 22.3 21.4 0.233
Sparc 22.7 21.6 0.022
Pgm1 22.0 21.6 0.012
Ldha 22.0 22.0 0.022
Col5a1 22.4 22.2 ,.001
Fbn1 22.8 22.3 0.002
Col5a3 22.2 22.4 0.001
Slc37a4 22.5 22.4 0.002
Pgam2 22.1 22.6 0.003
Col1a1 23.5 23.3 0.001
Col1a2 23.2 23.7 0.022
Pvalb 23.1 23.8 0.014
Col3a1 23.7 25.4 ,.001
Neu2 28.5 27.7 0.005
doi:10.1371/journal.pone.0007832.t005
Figure 1. Relationship between fold changes in gene expres-
sion by expression array versus qPCR. Correlation coefficients are
indicated for both Pearson’s and Spearman’s correlation methods.
doi:10.1371/journal.pone.0007832.g001
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CoA to form HMG-CoA; expression is known to increase in the
face of starvation [52]. High degrees of ketone body production
are hallmarks of both diabetic ketoacidosis and starvation ketosis.
Carbohydrate and Alcohol Metabolism
Nine genes with reduced expression were assigned to GO
groups related to various aspects of carbohydrate and alcohol
metabolism (Neu2, Pfk1, Slc37a4, Gpd2, Amy1, Pgam2, Ldha, Pgm1,
Dlat). Among these, Pfk1 catalyzes the reaction ATP+D-fructose 6-
phosphate=ADP+D-fructose 1,6-bisphosphate, and is a key
regulatory enzyme in glycolysis. Slc37a4 is involved in the
transmembrane transport of glycerol-6-phosphate; deficiency of
this enzyme in humans has been implicated as the cause of
glycogen storage disease type 1b [53] (in contrast to the more
common type 1a variant which is caused by deficiency of glucose-
6-phosphatase). Pgam2 catalyzes the interconversion of 3- and 2-
phosphoglycerate, and is involved in glycolysis-gluconeogenesis.
Ldha catalyzes the reaction (S)-lactate+NAD+=pyruvate+
NADH+H+, and thus is involved in pyruvate metabolism as well
as glycolysis-gluconeogenesis. Pgm1 connects glycolysis and
glycogen metabolism by interconverting glucose-1-phosphate and
glucose-6-phosphate. Dlat is one of three components of the
pyruvate dehydrogenase complex, which catalyzes the overall
conversion of pyruvate to acetyl-CoA and CO2. Several of these
genes have been shown previously to have altered expression
in type 1 diabetes, including decreased expression of Pgam and
Ldha in skeletal muscle [39] but increased expression of Ldha in
pancreas [54].
Protein Ubiquitination
There were four genes with increased expression related to
ubiquitin, Trim 63, Fbxo32, Rnf 39,a n dCblb. Ubiquitin ligases
catalyze the reaction ATP+ubiquitin+protein lysine=AMP+
diphosphate+protein N-ubiquityllysine. These enzymes catalyze
themediationofsubstraterecognitioninubiquitin-mediatedprotein
degradation, which involves adding one or more ubiquitin moieties
to the protein. Ubiquitin-mediated protein degradation has been
implicated in the pathophysiology of type 1 diabetes [39,55–57] as
well as other catabolic states which cause muscle atrophy [39,55].
Regarding individual genes within this group, increased expres-
sion of both Fbxo32 (also known as atrogin-1 and MAFbx)a n dTrim63
(also known as Murf1) have been demonstrated in diabetic limb
muscle [39,58]. Trim63 catalyzes ubiquitylation of the contractile
protein troponin I through a RING finger-dependent mechanism
[59]. Cblb is a major susceptibility gene for type 1 diabetes in the
Komeda diabetes-prone rat [60].
Oxidoreductase Activity
There were eight genes with increased expression in the
oxidoreductase GO group (Cyp2e1, Fmo3, Cryl1, Lox, CP, Decr1,
Aox1, Por). Oxidoreductases catalyze an oxidation-reduction
(redox) reaction, in which one substrate acts as a hydrogen or
electron donor and becomes oxidized and the other acts as a
hydrogen or electron recipient and becomes reduced. There is
considerable evidence implicating oxidative stress in the patho-
physiology of rodent experimental as well as human clinical type 1
diabetes [61]. Previous studies have found increased expression
with type 1 diabetes of Cyp2e1 in lymphocytes and heart and Cp in
corpus cavernosum, whereas Lox undergoes reduced expression in
cavernosum [35,38,62]. Cyp2e1 is of particular interest in that
protein levels increase in pancreas, liver, kidney and brain of type
1 diabetic rats in parallel to reactive oxygen species production
and lipid peroxidation; furthermore overexpression of Cyp2e1
augments both glutathione S-transferase A4-4 levels and mito-
chondrial reactive oxygen species [61].
Collagen and Extracelluar Matrix
There were seven genes with reduced expression in diabetic
diaphragm muscle related to collagen and extracellular matrix
(Fbn1, Sparc, and five collagen genes). Expression of Fbn1, Col1a1
and Col3a1 is reduced by type 1 diabetes in skeletal muscle [39],
expression of these three genes as well as Col5a3, Col5a1 and Sparc
is reduced by type 1 diabetes in corpus cavernosum [35], Sparc
expression is reduced in type 1 diabetic kidneys [63], and Fbn1 and
Col3a1 expression is reduced in type 1 diabetic heart muscle [38].
Morphogenesis, Organogenesis and Organ Development
There were ten genes with increased expression (Esm1, Okl38,
Mustn1, Omd, Spp1, Serpine1, Rnf39, Mafk, Gpnmb, Dyrk1a) and seven
genes with reduced expression (Col3a1, Pvalb, Acsl6, Ret, Cxcl12,
Rtn4, Ddah1) related to morphogenesis, organogenesis and organ
development, a group involved in the formation and organization
of tissue and organ structure. No obvious distinguishing features
could be discerned between constituent genes with increased
compared with decreased expression, except that the former
included three genes assigned to the GO group skeletal
development (Omd, Spp1, Gpnmb). Among genes with reduced
expression, Pvalb is of particular interest in that it binds calcium
thereby playing an important role in skeletal muscle relaxation.
Expression of Pvalb is decreased in skeletal muscle of streptozot-
ocin-diabetic rats [39].
Previous Gene Expression Array Studies of Limb Muscles
Several previous gene array studies have examined limb muscle
gene expression responses to diabetes. Most are of type 2 diabetes
[32,40,41] and will not be described here. Lecker et al. [39], on
the other hand, studied streptozotocin-induced type 1 diabetes,
similar to the present study. However their interest was to examine
skeletal muscle atrophy, and hence they focused on limb muscle
genes with altered expression that were common among four
models: diabetes, cancer, renal failure and fasting. Gene groups
with increased expression included those related to protein
degradation and ubiquitin as well as transcription and translation.
Reduced expression was found for groups of genes related to
carbohydrate metabolism, ATP synthesis, and extracellular matrix
proteins. Not described in any of the above four studies were
changed expression of genes related to two other groups identified
in the present study, oxidoreductase activity and morphogenesis/
organogenesis. Thus the present study demonstrates a number of
gene groups with altered expression in diaphragm that were
previously identified as being affected in diabetic limb muscle. It
also extends previous limb muscle findings by identifying two other
gene groups whose expression in diaphragm is modulated by
diabetes. One of these groups is related to oxidative stress, which
based on numerous studies in other tissues is felt to be an
important contributor to end-organ damage in diabetes [61].
Relationship of Changes in Gene Expression to Cellular
Function
Alterations in gene expression do not always parallel changes in
protein levels or cellular function. However, for the presently
demonstrated changes in gene expression there are data from
other studies suggesting that at least some of the changes in gene
expression correspond to post-transcriptional events that have
been described previously [6,8,15–27]. First, there is extensive
biochemical literature indicating that diabetes results in a shift in
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metabolism. Regarding the former, diabetic diaphragm has
reduced uptake and phosphorylation of glucose, phosphorylation
of fructose-6-phosphate, glycolysis, oxidation of pyruvate and
acetate, uptake of acetoacete, production of glycogen, the
proportion of the active complex of pyruvate dehydrogenase,
and activities of hexokinase, phosphorylase and phosphofructoki-
nase [15–22]. Regarding the latter, diabetic diaphragm has
increased fat metabolism, uptake and oxidation of free fatty acids,
output of glycerol (reflective of lipolysis), capacity for mobilization
of intracellular lipids, and intracellular concentrations of triglyc-
erides, free fatty acid and long-chain fatty acyl-CoA [22–25]. Thus
the present findings indicate that alterations in gene expression
contribute to the shift in cellular energetic patterns, and
furthermore elucidate which specific lipid (Cte1, Mte1) and
carbohydrate (Neu2, Pfkl, Slc37a4, Gpd2, Amy1, Pgam2, Ldha,
Pgm1, Dlat) metabolism genes are involved.
Second, there is at least one previous functional study
implicating heightened oxidative stress contributes to the impair-
ment of diaphragm contractile performance resulting from
diabetes. Hida et al. [6] administered N-acetylcysteine to rats
with streptozotocin-induced diabetes, and found an attenuation of
diabetes-induced contractile dysfunction. The present data thus
provide further support for the role of oxidative stress in diabetes-
induced diaphragm dysfunction by identifying eight genes related
to oxidoreductase activity (Cyp2e1, Fmo3, Cryl1, Lox, Cp, Decr1,
Aox1, Por) with increased expression in diabetic compared with
normal diaphragm.
In contrast, it appears that diabetes-induced electrophysiological
changes in diaphragm muscle can not be explained by changes in
gene expression. Previously described diaphragm electrophysio-
logical alterations include depolarization of resting membrane
potential, shortening of action potential duration and reduced
action potential area in an animal model of type 1 diabetes [26],
and increased action potential height in a model of type 2 diabetes
[27]. These electrophysiological parameters are regulated pre-
dominantly by Na+,K + and Cl- channels and transporters, and
no changes in expression exceeding 62-fold of relevant genes were
found in the present study.
PCR Verification of Gene Expression Array Findings
Of the 31 genes which underwent PCR testing, for one gene the
altered expression was in opposite directions with the two
techniques, and for five genes the PCR data was not statistically
significant although the direction of the changes paralleled that of
the array data. Among the latter group of five genes, the lack of
statistical significance for four genes (those with P values in the 0.05
to 0.25 range) most likely was due to the sample size, as the t-test
does not perform real well with modest sample sizes (in contrast to
BAM,usedforstatisticaltestingofthethearraydata,whichborrows
strength across the entire data set and thus is more robust with
modestsamplesizes). PCRdata forthefifthgene hada much higher
P value (0.488), and most likely the lack of significance would have
persisted even with larger sample sizes. The presence of a small
number of false positive findings is typical for gene expression array
technology due to the fact that expression of well over .10,000
genes is being tested simultaneously.
Methodological Issues
The present study used streptozotocin to produce diabetes. The
major effect of streptozotocin is on the pancreatic islet cells, and
thus in this model changes in other organs are believed to be due
predominantly to the diabetes and not the streptozotocin –
however it is certainly possible that some of the changes found in
the present study could be due to the acute toxic effect of the
streptozotocin. The present study used a single dose of
streptozotocin rather than repeated low doses, which is consistent
with previous studies of diaphragm muscle in streptozotocin-
induced diabetes [6–9,16,17,21,25,38] and previous gene expres-
sion array studies of other organ systems in streptozotocin-induced
diabetes [34–37].
The confirmatory PCR studies were performed on tissue from
the same animals used for the gene expression array studies.
Among fifteen previous gene expression array studies of diabetes
[28–41,64], twelve reported PCR data. Nine of the twelve
performed PCR on tissue from the same animals or humans as
the gene expression arrays, two studies performed PCR on tissue
from separate subjects, and one study performed PCR on 11 genes
using tissue from the same animals and on 3 genes using different
animals. Thus the majority of PCR data from previous gene
expression array studies of diabetes is derived from the same
animals or humans that were used for the expression arrays. In the
present study we therefore performed PCR studies in the same
animals as had been used in array studies in order to make our
study more directly comparable to previous work in this area.
Conclusions
In conclusion the present study found that diaphragm muscle
gene expression was modified in several important areas of cellular
function and structure in a model of type 1 diabetes. Reciprocal
changes in expression of genes involved in carbohydrate and lipid
metabolism may change the availability of energetic substrates and
thereby directly modulate fatigue resistance, an important issue for
a muscle like the diaphragm which needs to contract without rest
for the entire lifetime of the organism. Diabetes is well-established
to reduce cardiac muscle carbohydrate uptake and oxidation and
increase fatty acid metabolism, which is believed to directly impair
contractility and increase the severity of ischemic injury [65].
Interestingly, in type 1 diabetic heart there is more prominent
increased expression of lipid metabolism genes than decreased
expression of carbohydrate metabolism genes [36–38], whereas in
the type 1 diabetic diaphragm the number of carbohydrate genes
with decreased expression exceeds the number of lipid metabolism
with increased expression. Upregulation of ubiquitin-related gene
expression suggests a role for a specific pathway of protein
degradation, one of which has been demonstrated to have as its
target a member of the contractile apparatus. Augmented
oxidoreductase gene expression suggests that oxidative stress
may contribute to respiratory muscle dysfunction, as has been
implicated with diabetes in other tissues [61]. Finally, altered
expression of number of genes noted in the present study is also
found in a number of conditions leading to muscle atrophy, which
might contribute to respiratory muscle dysfunction in any state
associated with cachexia. Thus the present data suggest the
presence of several processes which contribute and possibly
interact to impair diaphragm muscle contractile function in type
1 diabetes, several of which are potentially amenable to
therapeutic interventions. A limitation of the present study is the
small number of animals studied with its effects on the robustness
of the findings. Future studies are needed to test the efficacy of
interventions which specifically address the processes suggested by
the present gene expression studies. One such study has already
been performed, namely the effects of the anti-oxidant N-
acetylcysteine [6], which did indeed attentuate the diabetes-
induced contractile dysfunction. Other studies could include
pharamacologic or dietary interventions which change cellular
substrate utilization patterns or drugs which modulate ubiquitin-
mediated protein degradation.
Diaphragm Muscle & Diabetes
PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7832Supporting Information
Appendix S1 Genes which underwent RT-PCR testing, and the
respective Applied Biosystems rat assay catalog numbers.
Found at: doi:10.1371/journal.pone.0007832.s001 (0.06 MB
DOC)
Appendix S2 Complete list of genes with statistically significant
changes of at least62-fold in diabetic compared with normal
diaphragm muscle.
Found at: doi:10.1371/journal.pone.0007832.s002 (0.15 MB
DOC)
Acknowledgments
We would like to thank Dr. Patrick Leahy from the Gene Expression Array
Core Facility of the Comprehensive Cancer Center of Case Western
Reserve University for his valuable assistance.
Author Contributions
Conceived and designed the experiments: EvL MM. Performed the
experiments: MM. Analyzed the data: EvL MM. Contributed reagents/
materials/analysis tools: EvL. Wrote the paper: EvL MM.
References
1. Wanke T, Formanek D, Auinger M, Popp W, Zwick H, et al. (1991) Inspiratory
muscle performance and pulmonary function changes in insulin-dependent
diabetes mellitus. Am Rev Resp Dis 143: 97–100.
2. Wanke T, Paternostro-Sluga T, Grisold W, Formanek K, Auinger M, et al.
(1992b) Phrenic nerve function in type 1 diabetic patients with diaphragm
weakness and peripheral neuropathy. Respiration 59: 233–237.
3. Wanke T, Lahrmann H, Auinger M, Merkle M, Formanek D, et al. (1993)
Endogenous opiod system during inspiratory loading in patients with type 1
diabetes. Am Rev Respir Dis 148: 1335–1340.
4. Fahim MA, el-Sabban F, Davidson N (1998) Muscle contractility decrement and
correlated morphology during the pathogenesis of striptozotocin-diabetic mice.
Anat Rec 251: 240–244.
5. Grossie J (1982) Contractile and electrical characteristics of extensor muscle
from alloxan-diabetic rats. An in vitro study. Diabetes 31: 194–202.
6. Hida W, Shindoh C, Satoh J, Sagara M, Kikuchi Y, et al. (1996) N-
Acetylcysteine inhibits loss of diaphragm function in streptozotocin-treated rats.
Am J Crit Care Med 153: 1875–1879.
7. McGuire M, MacDermott M (1998) The influence of streptozotocin-induced
diabetes and the antihyperglycaemic agent metformin on the contractile
characteristics and the membrane potential of the rat diaphragm. Exp Physiol
83: 481–487.
8. McGuire M, MacDermott M (1999) The influence of streptozotocin diabetes
and metformin on erythrocyte volume and on the membrane potential and the
contractile characteristics of the extensor digitorum longus and soleus muscles in
rats. Exp Physiol 84: 1051–1058.
9. McGuire M, Dumbleton M, MacDermott M, Bradford A (2001) Contractile and
electrical properties of sternohyoid muscle in streptozotocin diabetic rats. Clin
Exp Pharmacol Physiol 28: 184–187.
10. Paulus SF, Grossie J (1983) Skeletal muscle in alloxan diabetes: a comparison of
isometric contractions in fast and slow muscle. Diabetes 32: 1035–1039.
11. Wanke T, Formanek D, Auinger M, Zwick H, Irsigler K (1992) Pulmonary gas
exchange and oxygen uptake during exercise in patients with type 1 diabetes
mellitus. Diabet Med 9: 252–257.
12. Katoh J, Hara Y, Kurusu M, Miyaji J, Narutaki K (1996) Cardiorespiratory
function as assessed by exercise testing in patients with non-inuslin-dependent
diabetes mellitus. J Int Med Res 24: 209–213.
13. Regensteiner JG, Sippel J, McFarling ET, Wolfel EE, Hiatt WR (1995) Effects of
non-insulin-dependent diabetes on oxygen consumption during treadmill
exercise. Med Sci Sports Exerc 27: 661–667.
14. Scano G, Filippelli M, Romagnoli I, Mancini M, Misuri G, et al. (2000) Hypoxic
and hypercapnic breathlessness in patients with type I diabetes mellitus. Chest
117: 960–967.
15. Beatty CH, Peterson RD, Bocek RM, West ES (1959) Acetoacetate and glucose
uptake by diaphragm and skeletal muscle from from control and diabetic rats.
J Biol Chem 234: 11–15.
16. Beloff-Chain A, Rookledge KA (1968) The metabolism of glucose in diaphragm
muscle from normal rats, from streptozotocin-treated diabetic rats and from rats
treated with anti-insulin serum. Biochem J 110: 529–532.
17. Beloff-Chain A, Chain EB, Rookledge KA (1971) The influence of insulin and of
contraction on glucose metabolism in the perfused diaphragm muscle from
normal and streptozotocin-treated rats. Biochem J 125: 97–103.
18. Caterson ID, Fuller SJ, Randle PJ (1982) Effect of the fatty acid oxidation
inhibitor 2-tetradecylglycidic acid on pyruvate dehydrogenase complex activity
in starved and alloxan-diabetic rats. Biochem J 208: 53–60.
19. Foster JM, Villee CA (1954) Pyruvate and acetate metabolism in the isolated rat
diaphragm. J Biol Chem 211: 797–808.
20. Garland PB, Newsholme EA, Randle PJ (1964) Regulation of glucose uptake by
muscle. 9. Effects of fatty acids and ketone bodies, and of alloxan-diabetes and
starvation, on pyruvate metabolism and on lactate-pyruvate and L-glycerol 3-
phosphate-dihydroxyacetone phosphate concentration ratios in rat heart and rat
diaphragm muscles. Biochem J 93: 665–678.
21. Ianuzzo CD, Noble EG, Hamilton N, Dabrowski B (1982) Effects of
streptozotocin diabetes, insulin treatment, and training on the diaphragm.
J Appl Physiol 52: 1471–1475.
22. Randle PJ, Newsholme EA, Garland PB (1964) Regulation of glucose uptake by
muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-
diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart
and diaphragm muscles. Biochem J 93: 652–65.
23. Chorva ´thova ´ V, Ondreicka R, Ozdin L, Dzu ´rik R (1981) Metabolism of
palmitate-1-14C in the tissues of rats with streptozotocin diabetes. Physiol
Bohemoslov 30: 259–266.
24. Garland PB, Randle PJ (1964) Regulation of glucose uptake by muscles. 10.
Effects of alloxan-diabetes, starvation, hypophysectomy and adrenalectomy, and
of fatty acids, ketone bodies and pyruvate, on the glycerol output and
concentrations of free fatty acids, long-chain fatty acyl-coenzyme A, glycerol
phosphate and citrate-cycle intermediates in rat heart and diaphragm muscles.
Biochem J 93: 678–687.
25. Stearns SB, Tepperman HM, Tepperman J (1979) Studies on the utilization and
mobilization of lipid in skeletal muscles from streptozotocin-diabetic and control
rats. J Lipid Res 20: 654–662.
26. van Lunteren E, Moyer M (2003) Streptozotocin-diabetes alters action potentials
in rat diaphragm. Respir Physiol Neurobiol 135: 9–16.
27. van Lunteren E, Moyer M (2006) Altered diaphragm action potentials in Zucker
diabetic fatty (ZDF) rats. Respir Physiol Neurobiol 153: 157–165.
28. Garnett KE, Chapman P, Chambers JA, Waddell ID, Boam DS (2005)
Differential gene expression between Zucker Fatty rats and Zucker Diabetic
Fatty rats: a potential role for the immediate-early gene Egr-1 in regulation of
beta cell proliferation. J Mol Endocrinol 35: 13–25.
29. Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, et al. (2004) Gene
expression profiling in glomeruli from human kidneys with diabetic nephrop-
athy. Am J Kidney Dis 43: 636–650.
30. Fan Q, Shike T, Shigihara T, Tanimoto M, Gohda T, et al. (2003) Gene
expression profile in diabetic KK/Ta mice. Kidney Int 64: 1978–1985.
31. Wilson KH, Eckenrode SE, Li QZ, Ruan QG, Yang P, et al. (2003) Microarray
analysis of gene expression in the kidneys of new- and post-onset diabetic NOD
mice. Diabetes 52: 2151–2159.
32. Suh YH, Kim Y, Bang JH, Choi KS, Lee JW, et al. (2005) Analysis of gene
expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic
Zucker diabetic fatty rats. J Mol Endocrinol 34: 299–315.
33. Eckenrode SE, Ruan Q, Yang P, Zheng W, McIndoe RA, et al. (2004) Gene
expression profiles define a key checkpoint for type 1 diabetes in NOD mice.
Diabetes 53: 366–375.
34. Kubo E, Singh DP, Akagi Y (2005) Gene expression profiling of diabetic and
galactosaemic cataractous rat lens by microarray analysis. Diabetologia 48:
790–798.
35. Sullivan CJ, Teal TH, Luttrell IP, Tran KB, Peters MA, et al. (2005)
Microarray analysis reveals novel gene expression changes associated with
erectile dysfunction in diabetic rats. Physiol Genomics 23: 192–205.
36. Gerber LK, Aronow BJ, Matlib MA (2006) Activation of a novel long-chain free
fatty acid generation and export system in mitochondria of diabetic rat hearts.
Am J Physiol 291: C1198–C1207.
37. Knoll KE, Pietrusz JL, Liang M (2002) Tissue-specific transcriptome responses
in rats with early streptozotocin-induced diabetes. Physiol Genomics 21:
222–229.
38. van Lunteren E, Moyer M (2007) Oxidoreductase, morphogenesis, extracellular
matrix and calcium ion binding gene expression in streptozotocin-induced
diabetic rat heart. Am J Physiol Endocrinol Metab 293: E759–768.
39. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, et al. (2004) Multiple
types of skeletal muscle atrophy involve a common program of changes in gene
expression. FASEB J 18: 39–51.
40. Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS (2002) Gene expression
profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment.
Diabetes 51: 1913–1920.
41. Voss MD, Beha A, Tennagels N, Tschank G, Herling AW, et al. (2005) Gene
expression profiling in skeletal muscle of Zucker diabetic fatty rats: implications
for a role of stearoyl-CoA desaturase 1 in insulin resistance. Diabetologia 48:
2622–2630.
42. Porter JD, Merriam AP, Leahy P, Gong B, Feuerman J, et al. (2004) Temporal
gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm
identifies conserved and muscle-group specific mechanisms in the pathogenesis
of muscular dystrophy. Hum Mol Genet 13: 257–269.
Diaphragm Muscle & Diabetes
PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e783243. Rouger K, Le Cunff M, Steenman M, Potier MC, Gibelin N, et al. (2002)
Global/temporal gene expression in diaphragm and hindlimb muscles of
dystrophin-deficient (mdx) mice. Am J Physiol Cell Physiol 253: C773–C784.
44. van Lunteren E, Leahy P (2007) Gene expression microarrays and respiratory
muscles. Respir Physiol Neurobiol 156: 103–115.
45. van Lunteren E, Moyer M, Leahy P (2006) Gene expression profiling of
diaphragm muscle in alpha2-laminin (merosin)-deficient dy/dy dystrophic mice.
Physiol Genomics 25: 85–95.
46. van Lunteren E, Spiegler S, Moyer M (2008) Contrast between cardiac left
ventricle and diaphragm muscle in expression of genes involved in carbohydrate
and lipid metabolism. Respir Physiol Neurobiol 161: 41–53.
47. Ishwaran H, Rao JS (2003) Detecting differentially expressed genes in
microarrays using Bayesian model selection. J Am Stat Assoc 98: 438–455.
48. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: data
base for annotation, visualization, and integrated discovery. Genome Biol 4:
R60.
49. Hosack DA, Dennis G, Sherman BT, Lane HC, Lempicki RA (2003) Identifying
biological themes within lists of genes with EASE. Genome Biol 4: R70.
50. Durgan DJ, Smith JK, Hotze MA, Egbejimi O, Cuthbert KD, et al. (2006)
Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms
and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin.
Am J Physiol Heart Circ Physiol 290: H2480–2497.
51. Stavinoha MA, RaySpellicy JW, Essop MF, Graveleau C, Abel ED, et al. (2004)
Evidence for mitochondrial thioesterase 1 as a peroxisome proliferator-activated
receptor-alpha-regulated gene in cardiac and skeletal muscle. Am J Physiol
Endocrinol Metab 287: E888–895.
52. Ayte J, Gil-Gomez G, Haro D, Marrero PF, Hegardt FG (1990) Rat
mitochondrial and cytosolic 3-hydroxy-3-methylglutaryl-CoA synthases are
encoded by two different genes. Proc Natl Acad Sci 87: 3874–3878.
53. Lin B, Annabi B, Hiraiwa H, Pan CJ, Chou JY (1998) Cloning and
characterization of cDNAs encoding a candidate glycogen storage disease type
1b protein in rodents. J Biol Chem 273: 31656–31660.
54. Laybutt DR, Glandt M, Xu G, Ahn YB, Trivedi N, et al. (2003) Critical
reduction in beta-cell mass results in two distinct outcomes over time.
Adaptation with impaired glucose tolerance or decompensated diabetes. J Biol
Chem 278: 2997–3005.
55. Combaret L, Adegoke OA, Bedard N, Baracos V, Attaix D, et al. (2005) USP19
is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic
states. Am J Physiol Endocrinol Metab 288: E693–700.
56. Fernandes R, Carvalho AL, Kumagai A, Seica R, Hosoya K, et al. (2004)
Downregulation of retinal GLUT1 in diabetes by ubiquitinylation. Mol Vis 10:
618–628.
57. Liu Z, Miers WR, Wei L, Barrett EJ (2000) The ubiquitin-proteasome
proteolytic pathway in heart vs skeletal muscle: effects of acute diabetes.
Biochem Biophys Res Commun 276: 1255–1260.
58. Dehoux M, Van Beneden R, Pasko N, Lause P, Verniers J, et al. (2004) Role of
the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx
during fasting and diabetes. Endocrinology 145: 4806–4812.
59. Kedar V, McDonough H, Arya R, Li HH, Rockman HA, et al. (2004) Muscle-
specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac
troponin I. Proc Natl Acad Sci 101: 18135–18140.
60. Yokoi N, Komeda K, Wang HY, Yano H, Kitada K, et al. (2002) Cblb is a
major susceptibility gene for rat type 1 diabetes mellitus. Nat Genet 31: 391–394.
61. Raza H, Prabu SK, Robin MA, Avadhani NG (2004) Elevated mitochondrial
cytochrome P450 2E1 and glutathione S-transferase A4-4 in streptozotocin-
induced diabetic rats: tissue-specific variations and roles in oxidative stress.
Diabetes 53: 185–194.
62. Haufroid V, Ligocka D, Buysschaert M, Horsmans Y, Lison D (2003)
Cytochrome P4502E1 (CYP2E1) expression in peripheral blood lymphocytes:
evaluation in hepatitis C and diabetes. Eur J Clin Pharmacol 59: 29–33.
63. Gilbert RE, McNally PG, Cox A, Dziadek M, Rumble J, et al. (1995) SPARC
gene expression is reduced in early diabetes-related kidney growth. Kidney Int
48: 1216–1225.
64. Palsgaard J, Brøns C, Friedrichsen M, Dominguez H, Jensen M, et al. (2009)
Gene expression in skeletal muscle biopsies from people with type 2 diabetes and
relatives: differential regulation of insulin signaling pathways. PLoS ONE 4(8):
e6575. doi:10.1371/journal.pone.0006575.
65. Lopaschuk GD (2002) Metabolic abnormalities in the diabetic heart. Heart
Failure Rev 7: 149–159.
Diaphragm Muscle & Diabetes
PLoS ONE | www.plosone.org 9 November 2009 | Volume 4 | Issue 11 | e7832